The Need for Reducing Unnecessary Biopsies in Breast MRI Dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) of the breast—referred to as standard breast MRI throughout this chapter—is considered the most…
Abbreviations ADC apparent diffusion coefficient AUC area under the curve CAPIRINHA Controlled aliasing in parallel imaging results in higher acceleration CD Crohn disease CE contrast-enhanced CRC colorectal cancer CT computed…
Introduction Hybrid positron emission tomography (PET)/magnetic resonance imaging (MRI) is an emerging technology with promising applications in cancer evaluation ( ). The main advantage of these systems is that both…
Introduction Gynecologic malignancies are a considerable source of morbidity and mortality, accounting for nearly 672,000 deaths globally in 2020 ( ). Imaging complements surgical and clinical gynecologic cancer staging. Pelvic…
Introduction The use of positron emission tomography (PET) in the evaluation of genitourinary malignancies has traditionally been hampered by low tumor uptake and the masquerading effect of excreted radiopharmaceutical activity…
Introduction Positron emission tomography/magnetic resonance imaging (PET/MRI) is an innovative imaging technology that simultaneously acquires PET and MRI, allowing the integration of sensitive metabolic and functional information with precise structural…
Acknowledgments Funding was provided in part by the 2020–Research and Innovation Framework Program PHC-11-2015 Nr. 667211, Jubiläumsfonds of the Austrian National Bank # Nr: 18207and seed grants from Novomed Austria…
Primary bone and soft tissue malignancies Primary bone and soft tissue malignancies are a heterogeneous group of relatively rare tumors, most of them deriving from mesenchymal tissue (sarcomas). The reported…
Introduction Blood malignancies account for approximately 10% of newly diagnosed malignant tumors in the United States. While a large number of different blood cancer entities exist, three main groups are…
Acknowledgments This work was in part supported by a grant from the National Cancer Institute, grant number R01CA269231, and the Sarcoma Foundation of America. We thank Mehdi Khalighi, Dawn Holley,…
